GLP-1 and pregnancy are not a safe combination: GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are NOT recommended during pregnancy, and the FDA labeling advises stopping them
The analysis indicates that their concurrent application can result in improved outcomes across critical physiological domains, encompassing systemic metabolism, muscular functionality, and adipose tissue remodeling
A streamlined approach aligns labs with decision points, such as dose escalation or annual risk assessment
Many of these impurities (e.g., truncated sequences, modified residues, amino acid insertions, isomerization, aggregation products, etc.) may have physicochemical properties very similar to the therapeutic peptide
The treatment is tied to the condition